Clinical Trial Update: Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases [Phase 1]

View source ↗

Summary

A Phase 1 trial update notes completion of a study evaluating the safety and potential efficacy of a 1% topical KM-001 formulation for Punctate Palmoplantar Ker…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita
• Punctate Palmoplantar Keratoderma Type

Drugs mentioned

• KM-001

Snippet

Sponsor: Kamari Pharma Ltd | Conditions: Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Status: COMPLETED